• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Proteasome Inhibitor
    3 Drugs classified under this drug class

    All the Drug Class Drugs

    Bortezomib Teva 3.5 mg
    partial basket chart
    Bortezomib Teva 3.5 mg

    Proteasome Inhibitor. Bortezomib 3.5 mg.
    VIAL (pwdr. for sol. for inj. SC IV):1×3.5mg.
    Initial.  is 1.3 mg/m2. may be admin. IV  at a concent.  of 1 mg/mL, or SC at a concent. of 2.5 mg/mL. When admin. IV, Bortezomib is admin. as a 3 -5 second bolus IV inj. Not for intrathecal use. See lit.
    Tmt. of pts.  with multip.myeloma. Tmt. of pts. with mantle cell lymphoma who have received at least one prior ther. Bortezomib in comb. with rituximab, cyclophosphamide, doxorubicin and prednisone- tmt. of adult pts. with prev. untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplant.
    C/I: Pts. with hypersens. (not includ. local react.), anaphylactic react.  to bortezomib, boron, or mannitol. Pts. with acute diffuse  infiltrative pulmon. and pericard. dis. Intrathecal   admin. (due to fatal events).

    partial basket chart

    Proteasome Inhibitor. Carfilzomib 60 mg/vial.
    SINGLE USE VIALS (Pwdr. for sol. for
    inject.): I.V. over 2 to 10 min., on Days 1,
    2, 8, 9, 15, 16, foll. by a rest period from
    Days 17 to 28. Ea. 28day period is 1 tmt
    cycle. In Cycle 1, a dose is 20 mg/m².
    Dose must be indiv. adjust. accord.
    with med. cond. and param. Modify
    dos. based on toxic.
    Tmt. of pts. with multiple myeloma who
    have receiv. at least 2 prior ther. incl.
    bortezomib and an immunomodul. ag.
    and have demonstr. dis. progress. on or
    within 60 days of compl. the last ther.
    Appr. is based on response rate. Clinical
    benefit, such as impr. in surv./sympt., has
    not been verified.
    C/I: None.

    partial basket chart

    Proteasome Inhibitor. Bortezomib 3.5 mg.
    VIAL (pwdr for sol.): 1. Initial: 1-3 mg/m2 2
    x wkly for 2 wks (days 1, 4, 8, and 11)
    foll. by 10 day rest period (days 12-21).
    This 3 wk. period is a tmt. cycle. At
    least 72 hrs. should elapse betw.
    consec. doses. See lit.
    Myeloma in pts. who have receiv. at least
    two prior therapies and have shown
    disease progress. on the last ther.
    C/I: Hypersens., severe hepat. impair.